PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33509758-6 2021 The results of ELISA demonstrated significantly lowered levels of MMP-2 and MMP-9 in dihydromyricetin-treated cells. dihydromyricetin 85-101 matrix metallopeptidase 2 Homo sapiens 66-71 35112788-0 2022 Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases-2 expression in human nasopharyngeal carcinoma through extracellular signal-regulated kinase signaling pathway. dihydromyricetin 0-16 matrix metallopeptidase 2 Homo sapiens 52-79 35112788-6 2022 Gelatin zymography assay and western blotting assays demonstrated that DHM suppressed the enzyme activity and protein expression of matrix metalloproteinases-2 (MMP-2). dihydromyricetin 71-74 matrix metallopeptidase 2 Homo sapiens 132-159 35112788-6 2022 Gelatin zymography assay and western blotting assays demonstrated that DHM suppressed the enzyme activity and protein expression of matrix metalloproteinases-2 (MMP-2). dihydromyricetin 71-74 matrix metallopeptidase 2 Homo sapiens 161-166 25110435-13 2014 MMP2/9 activity was also inhibited by DHM exposure (SK-Hep-1 cells without DHM, 24 h: 600 +- 26 mumol/L vs 100 mumol/L DHM, 24 h: 100 +- 6 mumol/L, P < 0.001; MHCC97L cells without DHM, 24 h: 504 +- 32 mumol/L vs 100 mumol/L DHM 24 h: 156 +- 10 mumol/L, P < 0.001). dihydromyricetin 38-41 matrix metallopeptidase 2 Homo sapiens 0-6 25110435-13 2014 MMP2/9 activity was also inhibited by DHM exposure (SK-Hep-1 cells without DHM, 24 h: 600 +- 26 mumol/L vs 100 mumol/L DHM, 24 h: 100 +- 6 mumol/L, P < 0.001; MHCC97L cells without DHM, 24 h: 504 +- 32 mumol/L vs 100 mumol/L DHM 24 h: 156 +- 10 mumol/L, P < 0.001). dihydromyricetin 75-78 matrix metallopeptidase 2 Homo sapiens 0-6 25110435-13 2014 MMP2/9 activity was also inhibited by DHM exposure (SK-Hep-1 cells without DHM, 24 h: 600 +- 26 mumol/L vs 100 mumol/L DHM, 24 h: 100 +- 6 mumol/L, P < 0.001; MHCC97L cells without DHM, 24 h: 504 +- 32 mumol/L vs 100 mumol/L DHM 24 h: 156 +- 10 mumol/L, P < 0.001). dihydromyricetin 75-78 matrix metallopeptidase 2 Homo sapiens 0-6 25110435-13 2014 MMP2/9 activity was also inhibited by DHM exposure (SK-Hep-1 cells without DHM, 24 h: 600 +- 26 mumol/L vs 100 mumol/L DHM, 24 h: 100 +- 6 mumol/L, P < 0.001; MHCC97L cells without DHM, 24 h: 504 +- 32 mumol/L vs 100 mumol/L DHM 24 h: 156 +- 10 mumol/L, P < 0.001). dihydromyricetin 75-78 matrix metallopeptidase 2 Homo sapiens 0-6 25110435-13 2014 MMP2/9 activity was also inhibited by DHM exposure (SK-Hep-1 cells without DHM, 24 h: 600 +- 26 mumol/L vs 100 mumol/L DHM, 24 h: 100 +- 6 mumol/L, P < 0.001; MHCC97L cells without DHM, 24 h: 504 +- 32 mumol/L vs 100 mumol/L DHM 24 h: 156 +- 10 mumol/L, P < 0.001). dihydromyricetin 75-78 matrix metallopeptidase 2 Homo sapiens 0-6 25110435-16 2014 In addition, PKC-delta protein, a key protein in the regulation of MMP family protein expression, was up-regulated with DHM treatment. dihydromyricetin 120-123 matrix metallopeptidase 2 Homo sapiens 67-70 30259634-0 2018 Effects of dihydromyricetin on ARPE-19 cell migration through regulating matrix metalloproteinase-2 expression. dihydromyricetin 11-27 matrix metallopeptidase 2 Homo sapiens 73-99 30259634-4 2018 Our results revealed that DHM attenuated ARPE-19 cell invasion and migration by reducing matrix metalloproteinase-2 (MMP-2) expression. dihydromyricetin 26-29 matrix metallopeptidase 2 Homo sapiens 89-115 30259634-4 2018 Our results revealed that DHM attenuated ARPE-19 cell invasion and migration by reducing matrix metalloproteinase-2 (MMP-2) expression. dihydromyricetin 26-29 matrix metallopeptidase 2 Homo sapiens 117-122 30259634-6 2018 In conclusion, our findings shown that DHM inhibits human RPE cell migration through the inhibition of MMP-2 expression; therefore, DHM may have potential therapeutic value in treating PVR as adjuvant therapy. dihydromyricetin 39-42 matrix metallopeptidase 2 Homo sapiens 103-108 30259634-6 2018 In conclusion, our findings shown that DHM inhibits human RPE cell migration through the inhibition of MMP-2 expression; therefore, DHM may have potential therapeutic value in treating PVR as adjuvant therapy. dihydromyricetin 132-135 matrix metallopeptidase 2 Homo sapiens 103-108 31894675-5 2019 RESULTS: DHM concentration-dependently inhibited cell migration and invasion and downregulated matrix metalloprotein -2 (MMP-2) and phosphorylated JNK (pJNK) expression in MKN45 cells, followed by upregulation of E-cadherin and downregulation of Vimentin. dihydromyricetin 9-12 matrix metallopeptidase 2 Homo sapiens 95-119 31894675-5 2019 RESULTS: DHM concentration-dependently inhibited cell migration and invasion and downregulated matrix metalloprotein -2 (MMP-2) and phosphorylated JNK (pJNK) expression in MKN45 cells, followed by upregulation of E-cadherin and downregulation of Vimentin. dihydromyricetin 9-12 matrix metallopeptidase 2 Homo sapiens 121-126 31894675-6 2019 Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway. dihydromyricetin 18-21 matrix metallopeptidase 2 Homo sapiens 68-73 31894675-6 2019 Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway. dihydromyricetin 18-21 matrix metallopeptidase 2 Homo sapiens 184-189 31894675-6 2019 Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway. dihydromyricetin 135-138 matrix metallopeptidase 2 Homo sapiens 68-73 31894675-6 2019 Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway. dihydromyricetin 135-138 matrix metallopeptidase 2 Homo sapiens 184-189